// App-Quantinova.ai

PB0612 : Rivaroxaban Plasma Concentration Values and Risk Factors for Adverse Events in Patients Experiencing Bleeding: Results from a Prospective Study

Researchers

Presenter

  • J. Arjakse

Principal Investigators

  • R.E. Malmstrm

  • L. Gustafsson

  • H. Ilumets

  • J. Kostjuk

  • M. Mrk

  • M. Pikta

  • A. Pohanka

  • Y. Rnquist

  • T. Marandi

Medical Centers

  • North Estonia Medical Centre, Hospital Pharmacy, Tallinn, Estonia

  • Karolinska University Hospita,l Department of Oncology, Stockholm, Sweden

  • Karolinska Institutet. Department of Medicine. Stockholm, Sweden, Stockholm, Sweden

  • North Estonia Medical Centre, Emergency Internal Medicine Department, Tallinn, Estonia

  • North Estonia Medical Centre Foundation, Tallinn, Estonia

  • Tallinn University of Technology, Department of Health Technologies, Tallinn, Estonia

  • Karolinska Institutet, Department of medicine, Stockholm, Sweden

  • Karolinska Institute, Clinical Pharmacology, Stockholm, Sweden

  • North Estonia Medical Centre, Therapy Quality Division and Centre of Cardiology, Tallinn, Estonia

  • University of Tartu, Heart Clinic, Tartu, Estonia

Locations

  • Estonia

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

Outcome

  • N/A

Study Design

  • Drug-Drug Interaction

  • Multinational

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved